Deep learning–based attenuation correction for whole-body PET — a multi-tracer study with 18F-FDG, 68 Ga-DOTATATE, and 18F-Fluciclovine
A novel deep learning (DL)-based attenuation correction (AC) framework was applied to clinical whole-body oncology studies using 18 F-FDG, 68 Ga-DOTATATE, and 18 F-Fluciclovine. The framework used activity (λ-MLAA) and attenuation (µ-MLAA) maps estimated by the maximum likelihood reconstruction of...
Saved in:
Published in | European journal of nuclear medicine and molecular imaging Vol. 49; no. 9; pp. 3086 - 3097 |
---|---|
Main Authors | , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Berlin/Heidelberg
Springer Berlin Heidelberg
01.07.2022
Springer Nature B.V |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | A novel deep learning (DL)-based attenuation correction (AC) framework was applied to clinical whole-body oncology studies using
18
F-FDG,
68
Ga-DOTATATE, and
18
F-Fluciclovine. The framework used activity (λ-MLAA) and attenuation (µ-MLAA) maps estimated by the maximum likelihood reconstruction of activity and attenuation (MLAA) algorithm as inputs to a modified U-net neural network with a novel imaging physics-based loss function to learn a CT-derived attenuation map (µ-CT).
Methods
Clinical whole-body PET/CT datasets of
18
F-FDG (
N
= 113),
68
Ga-DOTATATE (
N
= 76), and
18
F-Fluciclovine (
N
= 90) were used to train and test tracer-specific neural networks. For each tracer, forty subjects were used to train the neural network to predict attenuation maps (µ-DL). µ-DL and µ-MLAA were compared to the gold-standard µ-CT. PET images reconstructed using the OSEM algorithm with µ-DL (OSEM
DL
) and µ-MLAA (OSEM
MLAA
) were compared to the CT-based reconstruction (OSEM
CT
). Tumor regions of interest were segmented by two radiologists and tumor SUV and volume measures were reported, as well as evaluation using conventional image analysis metrics.
Results
µ-DL yielded high resolution and fine detail recovery of the attenuation map, which was superior in quality as compared to µ-MLAA in all metrics for all tracers. Using OSEM
CT
as the gold-standard, OSEM
DL
provided more accurate tumor quantification than OSEM
MLAA
for all three tracers, e.g., error in SUV
max
for OSEM
MLAA
vs. OSEM
DL
: − 3.6 ± 4.4% vs. − 1.7 ± 4.5% for
18
F-FDG (
N
= 152), − 4.3 ± 5.1% vs. 0.4 ± 2.8% for
68
Ga-DOTATATE (
N
= 70), and − 7.3 ± 2.9% vs. − 2.8 ± 2.3% for
18
F-Fluciclovine (
N
= 44). OSEM
DL
also yielded more accurate tumor volume measures than OSEM
MLAA
, i.e., − 8.4 ± 14.5% (OSEM
MLAA
) vs. − 3.0 ± 15.0% for
18
F-FDG, − 14.1 ± 19.7% vs. 1.8 ± 11.6% for
68
Ga-DOTATATE, and − 15.9 ± 9.1% vs. − 6.4 ± 6.4% for
18
F-Fluciclovine.
Conclusions
The proposed framework provides accurate and robust attenuation correction for whole-body
18
F-FDG,
68
Ga-DOTATATE and
18
F-Fluciclovine in tumor SUV measures as well as tumor volume estimation. The proposed method provides clinically equivalent quality as compared to CT in attenuation correction for the three tracers. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 Takuya Toyonaga and Dan Shao contributed equally to this work. Takuya Toyonaga and Dan Shao are the co-first authors. |
ISSN: | 1619-7070 1619-7089 1619-7089 |
DOI: | 10.1007/s00259-022-05748-2 |